Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.3052W HIGH $1.32
Volume
2.01 K
Value Traded
0.20
Short % Float
0%
-9.76%Week
-5.93%1 Month
-88.57%3 Month
-96.06%6 Month
-100%5 Year
-100%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
5.39 M
EPS (TTM)
-
P/E Ratio
-
Ent. Value
-
Total Shares
-
Float Shares
-
Insiders
0.00%
Institutions
0.00%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|
PoA blends historical approval base rates, trial design score and FDA review track record.
PBLA Catalyst Timeline
Dated clinical, regulatory and corporate events for Panbela Therapeutics, Inc.
Past FDA Catalysts and PDUFA Decisions
How PBLA actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2025-03-31 | SBP-101 (Ivospemin) | Phase 3 interim results | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Clinical Trial Results
Readouts, endpoints and source filings for every PBLA program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Nant Capital, LLC10% Owner | BuyConversion | 0 | $0.00 | 11/15/2024 |
Hedge Fund 13F Activity
Hedge Funds invested in PBLA
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Ikarian Capital, LLC | 0.1 % | 750.00 K | 355.96 K | 5.19% ( 17.58 K) |
Ownership Trends
PBLA Short Interest
Shares sold short, counted twice a month.
0%
Short % of Float
of tradable shares sold short
3
Shares Sold Short
0.0% vs prior count
-
Days to Cover
trading days of normal volume to buy every short share back
785
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How PBLA ranks across every disease it competes in
Competitive Position is a premium feature
See how PBLA ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialPBLA News
PBLASun BioPharma Announces Execution of Reverse Stock Split Represents Next Step Toward National Securities Exchange Listing MINNEAPOLIS, MN
Sun BioPharma Announces Execution of Reverse Stock Split MINNEAPOLIS, MN, November 7, 2017 (GLOBE NEWSWIRE) - Sun BioPharma, Inc. (OTCQB: SNBP), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of pancreatic diseases, announced toda
Read more →PBLASun BioPharma Files Form 10-Q for Second Quarter 2017 and Provides Clinical Update Completion of Phase 1a Safety Trial expected in September 2017 Foundation for next Clinical study underway to continue moving the clinica
Sun BioPharma Files Form 10-Q for Second Quarter 2017 and Provides Clinical Update MINNEAPOLIS, MN, August 10, 2017 (GLOBE NEWSWIRE) - Sun BioPharma, Inc. (OTCQB: SNBP), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of pancreatic
Read more →PBLASun BioPharma Reports First Quarter 2017 Results Raises $3.1 million from the sale of convertible promissory notes Converts $3.1 million of debt and accrued interest into common stock MINNEAPOLIS, MN, MAY 11, 2017 (GLOBE
Sun BioPharma Reports First Quarter 2017 Results MINNEAPOLIS, MN, MAY 11, 2017 (GLOBE NEWSWIRE) - Sun BioPharma, Inc. (OTCQB: SNBP), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of pancreatic diseases, today provides financial r
Read more →PBLASun BioPharma Provides Phase 1 Trial Update; Patients Experience Early Signs of Efficacy Patients Enrolled in Sun BioPharma's Phase 1 Clinical Study of SBP-101 in Pancreatic Cancer Experience Early Signs of Efficacy Repo
Sun BioPharma Provides Phase 1 Trial Update; Patients Experience Early Signs of Efficacy MINNEAPOLIS, MN, March 30, 2017 (GLOBE NEWSWIRE) - Sun BioPharma, Inc. (OTCQB: SNBP), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of pancr
Read more →PBLASun BioPharma Reports Third Quarter 201 6 Results and Provides Clinical Progress Update Completed enrollment of second and third cohorts in Phase 1 clinical study of SBP-101; first-in-class proprietary compound designed
Sun BioPharma Reports Third Quarter 2016 Results and Provides Clinical Progress Update MINNEAPOLIS, MN, November 10, 2016 (GLOBE NEWSWIRE) - Sun BioPharma, Inc. (OTCQB: SNBP), a biopharmaceutical company developing disruptive therapies for the treatment of patients with pancreat
Read more →PBLASun BioPharma Files Form 10-Q for Second Quarter 201 6 and Provides Business Update Initiated second cohort in Phase 1 clinical study of SBP-101; first-in-class proprietary compound designed specifically for pancreatic d
Sun BioPharma Files Form 10-Q for Second Quarter 2016 and Provides Business Update MINNEAPOLIS, MN, August 11, 2016 (GLOBE NEWSWIRE) - Sun BioPharma, Inc. (OTCPink: SNBP), a biopharmaceutical company developing therapies for the treatment of pancreatic diseases, today released f
Read more →PBLASun BioPharma, Inc. Raises $2.0 Million Through Private Placement Transaction
Sun BioPharma, Inc. Raises $2.0 Million Through Private Placement Transaction MINNEAPOLIS, MN, (GLOBE NEWSWIRE)-JUNE 28, 2016. Sun BioPharma, Inc. (OTCPink: SNBP), a biopharmaceutical company developing therapeutics for the treatment of patients with pancreatic diseases, today a
Read more →PBLASun BioPharma Provides Business Update and Reports Financial Results for Q1 2016 Completes enrollment of first cohort in Phase 1 clinical study of SBP-101; first-in-class proprietary compound designed specifically for pa
Sun BioPharma Provides Business Update and Reports Financial Results for Q1 2016 MINNEAPOLIS, MN, May 12, 2016 (GLOBE NEWSWIRE)-Sun BioPharma, Inc. (OTCPink: SNBP), a biopharmaceutical company developing therapies for the treatment of pancreatic diseases, today provided a busine
Read more →PBLASun BioPharma Reports Financial Results for Year Ended
Sun BioPharma Reports Financial Results for Year Ended December 31, 2015 and Provides Business Update MINNEAPOLIS, MN, March 8, 2016 (GLOBE NEWSWIRE)-Sun BioPharma, Inc. (OTCPink: SNBP), a biopharmaceutical company developing therapies for the treatment of pancreatic diseases, t
Read more →PBLADr. Dalvir S. Gill Appointed to Sun BioPharma Board of Directors Minneapolis, MN, March 3 , 2016 - Sun BioPharma, Inc., (OTCPink: SNBP), a biopharmaceutical company developing therapies for pancreatic diseases whose lead
Dr. Dalvir S. Gill Appointed to Sun BioPharma Board of Directors Minneapolis, MN, March 3, 2016- Sun BioPharma, Inc., (OTCPink: SNBP), a biopharmaceutical company developing therapies for pancreatic diseases whose lead product candidate, SBP-101, has recently entered first in hu
Read more →PBLAScott Kellen Appointed Chief Financial Officer of Sun BioPharma Healthcare Executive Brings Extensive Public Company Financial Experience to Leadership Team Minneapolis, MN
Scott Kellen Appointed Chief Financial Officer of Sun BioPharma Healthcare Executive Brings Extensive Public Company Financial Experience to Leadership Team Minneapolis, MN, October 2, 2015- Sun BioPharma, Inc., (OTCPink: SNBP), a biopharmaceutical company developing therapies
Read more →PBLAJ. Robert Paulson and Jeffrey Mathiesen Appointed to Sun BioPharma Board of Directors Two Experienced Healthcare Executives Join Board as Company Prepares to Enroll First Patient in Phase 1 Clinical
J. Robert Paulson and Jeffrey Mathiesen Appointed to Sun BioPharma Board of Directors Two Experienced Healthcare Executives Join Board as Company Prepares to Enroll First Patient in Phase 1 Clinical Trial Minneapolis, MN, September 30, 2015- Sun BioPharma, Inc., (OTCPink: SNBP)
Read more →PBLASUN BIOPHARMA, INC. Financial Statements Index to Financial Statements Audited Financial Statements (as of
Financial Statements Index to Financial Statements Audited Financial Statements (as of December 31, 2014 and 2013 and for the years ended December 31, 2014 and 2013) Report of Independent Auditor F-2 Consolidated Balance Sheets F-3 Consolidated Statements of Operations and Com
Read more →About Panbela Therapeutics, Inc.
Headquarters712 Vista Boulevard
Founded03-01-2017
BIOPHARMAWATCH ELITE
Trade the next PBLA catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $24/mo billed annually.
Cancel anytime